Testing negative for estrogen receptors (ER-), progesterone receptors (PR-), and HER2 (HER2-) on a pathology report means the cancer is "triple-negative". These negative results indicate the growth of the cancer is not supported by the hormones estrogen and progesterone, nor by the presence ...
The investigators reported that adding chemotherapy to endocrine therapy did not improve outcomes for postmenopausal women with low-risk, node-positive, hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2-) breast cancer in comparison to endocrine therapy alone. T...
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res. 2012, 40, 6319-6337. [CrossRef] [PubMed]Thiel, K.W.; Hernandez, L.I.; Dassie, J.P.; Thiel, W.H.; Liu, X.; Stockdale, K.R.; Rothman, A.M.; Hernandez, F.J.; McNamara...
Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis PurposeTo perform a meta-analysis in order to quantify the actual cumulative randomized evidence for the benefit and toxicity of trastuzumab combined with ... A Valachis...
Carol Kwok, who led the study, said that pre-surgery chemotherapy may bring "new hopes" for breast cancer patients as a higher pathological complete response (PCR) rate was observed in some aggressive tumor types such as the HER2-positive and the triple-negative breast cancers. ...
Breast cancer types The study looked at over 10,000 women with one specific type of breast cancer known as hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative, lymph node–negative breast cancer. Not all breast tumours behave the same way, with ...
in breast cancer cell lines Ghada A. Abdel-Latif1, Ahmed M. Al-Abd2,3, Mariane G. Tadros1, Fahad A. Al-Abbasi4, Amany E. Khalifa1,5 & Ashraf B. Abdel-Naim1 Herceptin is considered an essential treatment option for double negative breast cancer. Resveratrol...
For this particular arm of the I-SPY 2 trial, investigators sought to determine whether the neoadjuvant combination of olaparib, durvalumab, and paclitaxel would increase pCR rates compared with chemotherapy alone in HER2-negative biomarker subgroups of patients with stage II/III bre...
While one standard first-line treatment for patients with hormone receptor–positive/HER2-negative advanced breast cancer remains a CDK4/6 inhibitor given with ET, chemotherapy given as induction treatment is often used for patients who are at risk ...
Among HER2-positive breast cancer patients treated with chemotherapy alone, women with high levels of stromal tumor-infiltrating lymphocytes had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.